Understanding the Current Rating
The current Sell rating on 3B Blackbio DX Ltd is the result of a comprehensive evaluation across four key parameters: Quality, Valuation, Financial Trend, and Technicals. This rating suggests that investors should exercise caution, as the stock’s prospects appear limited relative to its risks and current market valuation.
Quality Assessment
As of 01 January 2026, 3B Blackbio DX Ltd holds an average quality grade. The company’s long-term growth has been disappointing, with net sales declining at an annualised rate of -10.27% over the past five years. Operating profit has also contracted sharply, falling by -16.77% annually during the same period. These figures indicate challenges in sustaining profitable growth, which weighs heavily on the quality assessment.
Valuation Considerations
The stock is currently classified as very expensive. Trading at a price-to-book value of 4, it commands a significant premium compared to its peers’ historical valuations. Despite a return on equity (ROE) of 16.5%, the elevated valuation raises concerns about the stock’s price sustainability. Investors should note that the company’s PEG ratio stands at 1.9, reflecting a valuation that may not be fully justified by its earnings growth prospects.
Financial Trend Analysis
The financial trend for 3B Blackbio DX Ltd is flat, signalling stagnation in recent performance. The latest quarterly results for September 2025 show a decline in profit before tax excluding other income (PBT LESS OI) to ₹14.11 crores, down by -11.09%. While profits have risen by 13.2% over the past year, this has not translated into positive stock returns, which have fallen by -27.78% over the same period. This divergence between profit growth and share price performance highlights underlying concerns about the company’s operational momentum and market sentiment.
Register here to know the latest call on 3B Blackbio DX Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Technical Outlook
The technical grade for the stock is mildly bearish. Recent price movements reflect this sentiment, with the stock declining by -0.35% on the latest trading day and showing a negative return of -27.78% over the past year. Although there was a short-term gain of +11.20% in the last month, the overall trend remains subdued. The stock has underperformed the broader market, as the BSE500 index has delivered a positive return of 6.11% over the same one-year period.
Market Position and Investor Interest
3B Blackbio DX Ltd is classified as a small-cap company within the Healthcare Services sector. Despite its size, domestic mutual funds hold no stake in the company as of the current date. This absence of institutional interest may reflect concerns about the company’s valuation or business fundamentals. Institutional investors typically conduct thorough research and their lack of participation can be a cautionary signal for retail investors.
Summary for Investors
In summary, the Sell rating on 3B Blackbio DX Ltd reflects a combination of average quality, very expensive valuation, flat financial trends, and a mildly bearish technical outlook. Investors should be aware that the stock has underperformed the market significantly over the past year and faces challenges in sustaining growth. The premium valuation relative to earnings and book value suggests limited upside potential at current levels.
For those considering exposure to this stock, it is important to weigh these factors carefully and monitor any changes in the company’s operational performance or market conditions that could alter its outlook.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Key Financial Metrics as of 01 January 2026
Market capitalisation remains in the small-cap range, reflecting the company’s modest size within the Healthcare Services sector. The stock’s one-day price change was -0.35%, with a one-week decline of -3.76%. Over the last six months, the stock has fallen by -4.76%, while the year-to-date return is -0.35%. The one-year return of -27.78% starkly contrasts with the broader market’s positive performance, underscoring the stock’s relative weakness.
Long-term growth rates remain negative, with net sales shrinking annually by -10.27% and operating profit declining by -16.77% over five years. The company’s return on equity of 16.5% is respectable but insufficient to justify the very expensive valuation at a price-to-book ratio of 4. The PEG ratio of 1.9 further indicates that earnings growth is not keeping pace with the stock’s valuation premium.
Profit before tax excluding other income for the September 2025 quarter stood at ₹14.11 crores, down by -11.09%, signalling recent operational challenges. Despite this, profits have increased by 13.2% over the past year, a positive sign that has not yet translated into share price gains.
Overall, the data paints a picture of a company facing headwinds in growth and valuation, with limited technical support for a bullish outlook.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
